Evidence map›Paper›PMID 39844912›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis.

Rebecca E Bignold, Hannah Busby, Jenny Holloway, Aaishah Kasu, Sonia Sian, Jill R Johnson

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HuR Regulates GATA3-Driven Type 2 Inflammation in CD4bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca E BignoldSchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
Hannah BusbySchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
Jenny HollowaySchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
Aaishah KasuSchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
Sonia SianSchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
Jill R JohnsonSchool of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allergic asthma is a highly prevalent chronic inflammatory disease driven by aeroallergen exposure. In severe asthma, the current standard of care does not fully control disease symptoms, indicating an unmet clinical need. Biologic therapies targeting cytokines IL-4, IL-5, and IL-13 have been shown to provide benefits to asthmatic patients over currently existing asthma treatments. Objective: We sought to review the effects of recently developed biologic therapies for asthma treatment. Methods: In this meta-analysis, the impact of IL-5 and IL-4/IL-13 biologic inhibitors was critically appraised considering overall lung function, symptom control, and oral corticosteroid use in asthmatic patients. Trials were identified using PubMed, Web of Science, Scopus, and clinicaltrials.gov. Clinical trials assessing severe asthmatic participants older than 12 years were included. Results: The meta-analysis included 6600 participants from 14 trials published in 2013 to 2020. For IL-5 inhibitors, improvements in FEV Conclusions: Biologic inhibitors targeting T

Indexed as

Asthmabiologicscytokineinflammationpharmacotherapy

Identifiers

PMID39844912
PMCPMC11751513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.